Evidence map›Paper›PMID 29094184›Full record

ArticleCancer immunology, immunotherapy : CII2018

BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.

Qi Liu, Hongda Zhu, Yun Liu, Sara Musetti, Leaf Huang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Immunotherapy for pediatric low-grade gliomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Review
  5. Review
  6. Article
  7. Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Review
  10. Circular RNA vaccine in disease prevention and treatment.Signal transduction and targeted therapy · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Combination therapies utilizing neoepitope-targeted vaccines.Cancer immunology, immunotherapy : CII · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Qi LiuDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1315 Kerr Hall, Campus Box 7571, Chapel Hill, NC, 27599, USA.
Hongda ZhuDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1315 Kerr Hall, Campus Box 7571, Chapel Hill, NC, 27599, USA.
Yun LiuDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1315 Kerr Hall, Campus Box 7571, Chapel Hill, NC, 27599, USA.
Sara MusettiDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1315 Kerr Hall, Campus Box 7571, Chapel Hill, NC, 27599, USA.
Leaf HuangDivision of Pharmacoengineering and Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1315 Kerr Hall, Campus Box 7571, Chapel Hill, NC, 27599, USA. leafh@unc.edu.
University of North Carolina at Chapel Hill · USHubei University of Technology · CN

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Small Animal Imaging CoreU54CA198999 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KABANOV, ALEXANDER V · 2015 to 2019
$11.9M
Nanocrystals for the Treatment of Multidrug Resistance in CancerR01CA149387 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HUANG, LEAF · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA149387NCI NIH HHS U54 CA198999NIH HHS CA149387NIH HHS CA198999
6 · The paper itself

Abstract

Approximately, 50% of human melanomas are driven by BRAF mutations, which produce tumors that are highly immunosuppressive and often resistant to vaccine therapy. We introduced lipid-coated calcium phosphate nanoparticles (LCP NPs) as a carrier to efficiently deliver a tumor-specific antigen, the BRAF

Indexed as

AnimalsCancer VaccinesCell Line, TumorFemaleMelanoma, ExperimentalMiceMice, Inbred C57BLProto-Oncogene Proteins B-rafTumor MicroenvironmentBraf protein, mouseCancer VaccinesProto-Oncogene Proteins B-rafBRAF-mutant melanomaImmunotherapyNanoparticlesPeptide vaccine

Identifiers

PMID29094184
PMCPMC5801101
OpenAlexW2767099463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.